The Eugene facility, with more than 20 years of history, houses a 16,000-square-foot R&D lab and a newly constructed 30,000-square-foot manufacturing facility
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats
The feature will be available across all Max Healthcare facilities, offering patients consistent and convenient access to services nationwide
The BD Neopak Glass Prefillable Syringe platform is designed for the complex needs of biologics and combination products
The collaboration gives Axolabs access to Codexis’ innovative RNA manufacturing technology
The company is rolling out ARTEMIS, a next-generation AI platform for capsid design
Subscribe To Our Newsletter & Stay Updated
